Glomerular filtration rate test

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$748,036.00
Award Year:
2010
Program:
SBIR
Phase:
Phase II
Contract:
2R44DK078404-02A1
Award Id:
85572
Agency Tracking Number:
DK078404
Solicitation Year:
n/a
Solicitation Topic Code:
NIDDK
Solicitation Number:
n/a
Small Business Information
BIOPAL, INC, 80 WEBSTER ST, WORCESTER, MA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
009796223
Principal Investigator:
CHRISTOPHERREINHARDT
(508) 770-1190
CS@BIOPAL.COM
Business Contact:
CHRISTOPHERREINHARDT
() -
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Kidney disease in the United States has been described as an epidemic. More than 20 million patients have chronic kidney disease (CKD) and these numbers are increasing annually. As a result, the number of patients with end-stage renal disease (ESRD) is expected to double between 1999 and 2010. These increases in CKD and ESRD are associated with significant morbidity, mortality and healthcare costs. Early detection and treatment of kidney disease has been shown to improve outcomes, but kidney disease is often under diagnosed resulting in lost opportunities to treat. The importance of early diagnosis and treatment of kidney disease has been extensively reviewed and published as a K/DOQI clinical practice guideline by the Na tional Kidney Foundation. Monitoring changes in glomerular filtration rate (GFR) provides the best means for early detection of kidney disease. The test that is most widely used in the US to screen abnormalities in GFR is serum creatinine. However, estimat ed GFR values using serum creatinine have limited diagnostic value over methods that directly measured GFR using an ideal filtration marker, such as inulin. This Phase II application seeks support to further develop a novel readout system, based on immunoa ssay technology, to directly measure GFR. As demonstrated during Phase I, our test is accurate, simple-to-use, inexpensive and can be widely assessable. The test utilizes FDA-cleared compounds that are known to be GFR markers. As a result, our proposed GFR test will be able to more quickly enter the marketplace. PUBLIC HEALTH RELEVANCE: The project will further develop a diagnostic test to measure kidney function. The test will utilize well-known and widely available analytical technology and will ut ilize clinically available compounds. Therefore, this test will be able to quickly enter the market-place.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government